HOME >> MEDICINE >> NEWS
Data on herceptin for early breast cancer currently insufficient for decision on its use

Yesterday Patricia Hewitt, the UK's Health Secretary, intervened directly to mediate a debate about access to the drug Herceptin for patients with early breast cancer. However, the available evidence on the efficacy and safety of Herceptin for early breast cancer is insufficient to make any reliable judgements, states an editorial by The Lancet published online today (Wednesday November 9, 2005). The UK's National Institute for Health and Clinical Excellence (NICE) should be given time to consider the evidence on the drug and must resist pressure from external groups, whatever the urgency and however well meaning, states The Lancet.

The studies on the use of Herceptin for early breast cancer were recently published in the New England Journal of Medicine (NEJM). An accompanying editorial in the NEJM stated that Herceptin "maybe even a cure" for breast cancer. However, the two studies represent interim efficacy analyses--a type of analyses that may show implausibly large treatment effects. A review in The Journal of the American Medical Association (JAMA) last week said, "clinicians should view the results of such trials with scepticism". The Lancet also notes that the two reports use different dosing regimens, making comparisons and conclusions difficult. Comparisons are further hampered by the omission of crucial overall and disease-free survival data, as well as information on cardiotoxicity. However, it is clear that Herceptin can precipitate severe heart failure in some patients, states the editorial.

The Lancet concludes: "The best that can be said about Herceptin's efficacy and safety for the treatment of early breast cancer is that the available evidence is insufficient to make reliable judgments. It is profoundly misleading to suggest, even rhetorically, that the published data may be indicative of a cure for breast cancerDrug regulatory agencies and bodies such as NICE play an important part in translating research evidence into clinical
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
9-Nov-2005


Page: 1 2

Related medicine news :

1. Study finds cardiac toxicity rates high with herceptin use
2. Lack of response to herceptin may be reversed with addition of a PI3K inhibitor
3. Pot bellies linked to early signs of cardiovascular disease
4. U of M report says early-childhood intervention improves well-being through young adulthood
5. Method shows promise for early detection of pancreatic cancer
6. Treatment for early prostate cancer associated with type of specialist seen
7. Medical management of another condition may not lead to early cancer diagnosis
8. Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
9. Study supports activity of GEMZAR in the treatment of early-stage breast cancer
10. Innovative device to treat brain cancer shows promise in early studies
11. Advances in screening and markers improve early detection of colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... the American Foundation for Suicide Prevention’s (AFSP) annual signature event, Out of the ... hundreds of U.S. cities to raise awareness of suicide prevention. To ensure Associate ...
(Date:9/3/2020)... ... September 03, 2020 , ... International ... Technologies WALI wireless parking lot controller. This advanced LED wireless dimming controller, along ... trespass, and protecting the night sky against light pollution. Leo Smith, the Northeast ...
(Date:9/1/2020)... ... , ... Feeding Matters , the first organization in the world dedicated ... pleased to announce that the U.S. Centers for Disease Control and Prevention (CDC) has ... edition of the U.S. International Classification of Diseases (ICD ) on October 1, ...
(Date:8/31/2020)... ... August 31, 2020 , ... The Lymphoma Research ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... of Blood Cancer Awareness Month (BCAM) and its international Light it Red ...
(Date:8/31/2020)... ... 2020 , ... Genesis Chiropractic Software and Billing Network ... of its integrated, HIPAA compliant, telehealth solution, available to US-based clients immediately. With ... seconds. , According to the U.S. Department of Health & Human Services, ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... September 03, 2020 , ... ... can safely return to schools and classrooms across the United States, IntraLogic ... its technology product line. TEMPE is a non-contact, wall-mounted scanning thermometer that rapidly ...
(Date:9/1/2020)... SANTA CLARA, Calif. (PRWEB) , ... September 01, ... ... diagnostics, and analytical laboratory technologies, will host the Agilent Science and Technology ... , During this two-day symposium, Agilent will open a suite of Live webinars ...
(Date:9/1/2020)... ... , ... Breast and ovarian cancers are common diseases that affect many women. ... (about 7,500 women per year) and 10% of ovarian cancers (about 2,000 women per ... are detectable in the Women’s Excellence Genetic Testing Program. , Dr. Jonathan Zaidan, MD, ...
Breaking Medicine Technology:
Cached News: